Evidence map›Paper›PMID 42237537›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Depletion of CD8

Qian Chen, David Sedloev, Hao Yao, Lianghao Mao, Dominic Depke, Lei Wang, Marina Scheller, Bailin He, Yi Liu, Julia M Unglaub and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qian ChenDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany; Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
David SedloevDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Hao YaoDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Lianghao MaoProteomics and Cancer Cell Signaling Group, Clinical Cooperation Unit Pediatric Leukemia, German Cancer Research Center and Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, 69120 Heidelberg, Germany.
Dominic DepkeDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Lei WangDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Marina SchellerDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Bailin HeDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yi LiuDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Julia M UnglaubDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Anita SchmittDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Ashok Kumar JayaveluProteomics and Cancer Cell Signaling Group, Clinical Cooperation Unit Pediatric Leukemia, German Cancer Research Center and Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, 69120 Heidelberg, Germany; Hopp Children's Cancer Center, 69120 Heidelberg, Germany.
Carsten Müller-TidowDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Michael SchmittDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Tim SauerDepartment of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany. Electronic address: tim.sauer@med.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor T (CART) cell therapy has demonstrated clinical efficacy in hematologic malignancies; however, primary or secondary treatment failure remains a major obstacle to durable responses. Defining the optimal cellular composition of CART products therefore represents a critical unmet need. Here, we show that CARTs targeting acute leukemias achieve maximal efficacy when composed exclusively of CD4

Indexed as

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesImmunotherapy, AdoptiveLeukemiaReceptors, Antigen, T-CellAnimalsApoptosisCell Line, TumorCell ProliferationCoculture TechniquesHumansMiceProteomicsXenograft Model Antitumor AssaysReceptors, Antigen, T-Cellacute leukemiaCD19.CARTCD33.CARTCD4(+)CARTCD70.CARTCD8(+) CART

Identifiers

PMID42237537
PMCPMC13464297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.